Cargando…
Oncogenic mutations within the β3‐αC loop of EGFR/ERBB2/BRAF/MAP2K1 predict response to therapies
BACKGROUND: β3‐αC loop is a highly conserved structural domain across oncogene families, which is a switch for kinase activity. There have been numerous researches on mutations within β3‐αC loop in EGFR, but relatively less in ERBB2, BRAF, and MAP2K1. In addition, previous studies mainly focus on β3...
Autores principales: | Zhang, Biao, Chen, Yongsheng, Dai, Pingping, Yu, Haoda, Ma, Jianhui, Chen, Chen, Zhang, Yan, Guan, Yanfang, Chen, Rongrong, Liu, Tao, Wang, Jiayin, Yang, Ling, Yi, Xin, Xia, Xuefeng, Ma, Haitao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7549570/ https://www.ncbi.nlm.nih.gov/pubmed/32757330 http://dx.doi.org/10.1002/mgg3.1395 |
Ejemplares similares
-
BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
por: Miele, Evelina, et al.
Publicado: (2020) -
ERBB2 oncogenicity: ERBIN helps to perform the job
por: Mei, Lin, et al.
Publicado: (2015) -
miR-524-5p suppresses the growth of oncogenic BRAF melanoma by targeting BRAF and ERK2
por: Liu, Szu-Mam, et al.
Publicado: (2014) -
The feasibility of using mutation detection in ctDNA to assess tumor dynamics
por: Yi, Xin, et al.
Publicado: (2017) -
Expression of oncogenes in thyroid tumours: coexpression of c-erbB2/neu and c-erbB.
por: Aasland, R., et al.
Publicado: (1988)